Birchview Capital’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Birchview Capital’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-128,000	Closed	-$19K	–	56
2019 Q3	$19K	Hold	128,000	–	–	0.01%	50
2019 Q2	$20K	Hold	128,000	–	–	0.01%	54
2019 Q1	$25K	Hold	128,000	–	–	0.02%	53
2018 Q4	$90K	Hold	128,000	–	–	0.09%	49
2018 Q3	$157K	Hold	128,000	–	–	0.1%	49
2018 Q2	$142K	Hold	128,000	–	–	0.1%	49
2018 Q1	$257K	Hold	128,000	–	–	0.17%	42
2017 Q4	$154K	Hold	128,000	–	–	0.09%	35
2017 Q3	$161K	Hold	128,000	–	–	0.08%	34
2017 Q2	$170K	Buy	128,000 +60,000	+88%	+$86.7K	0.09%	35
2017 Q1	$126K	Buy	68,000 +20,000	+42%	+$90.5K	0.07%	41
2016 Q4	$249K	Buy	48,000 +14,000	+41%	+$73.7K	0.15%	32
2016 Q3	$189K	Buy	+34,000	New	+$194K	0.11%	39

Other funds holding GNMX

AMCA

Arthur M. Cohen & Associates Northbrook, Illinois $563M AUM 20.97% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Birchview Capital's GNMX Position: Q4 2019 in Review

Birchview Capital sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2019, closing a stake of 128,000 shares — an estimated $19K sold.

Birchview Capital first reported a position in GNMX in Q3 2016 and held it in 13 quarters. The position peaked at $257K in Q1 2018. 28 funds tracked by Wall St. Rank hold GNMX as of Q4 2019.

Birchview Capital reported no remaining Aevi Genomic Medicine Inc position as of Q4 2019 after selling out during the quarter.
Birchview Capital sold 128,000 Aevi Genomic Medicine Inc shares in Q4 2019, an estimated $19K.
Birchview Capital first reported a position in Aevi Genomic Medicine Inc in Q3 2016 and held it in 13 quarters.
Birchview Capital's Aevi Genomic Medicine Inc position peaked at $257K in Q1 2018.
28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2019.

Based on Birchview Capital's 13F filing for Q4 2019, filed 12 Feb 2020.